RxDoctor Payments Data

Ellen Moreland

Adult Health · Glenwood, ARNPI 1720215205

Payments from drug & device makers

$707in general payments, 2019–2025

Across 30 payments — averaging $23.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$156
  • Exact Sciences$154
  • Amgen$68
  • Pfizer$62
  • Meridian Bioscience Inc.$57
  • AstraZeneca$49
  • plus $160 from 8 others

What the payments were for

  • Food & beverage$707100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$707 in reported general payments places this provider in the 50th percentile of 154 adult health providers in Arkansas.

See all adult health providers in Arkansas

Medicare billing

Part B allowed, 2024
$99,159
Medicare patients
379
Services billed
3,853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban75$69,100
OzempicSemaglutide56$55,517
TrulicityDulaglutide30$34,459
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$26,602
JardianceEmpagliflozin26$21,617
MounjaroTirzepatide14$16,607
FarxigaDapagliflozin Propanediol31$16,114
LinzessLinaclotide23$15,602
JanuviaSitagliptin Phosphate19$10,491
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,577
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,980
Praluent PenAlirocumab13$6,249
Xigduo XrDapaglifloz Propaned/Metformin11$5,858
Breo ElliptaFluticasone/Vilanterol12$4,759
SymbicortBudesonide/Formoterol Fumarate19$4,360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$62$69,10075 claims
Novo NordiskOzempic$29$55,51756 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$49$27,45361 claims
AbbVieLinzess$28$15,60223 claims
MerckJanuvia$15$10,49119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 154 adult health providers in Arkansas.

Other adult health in Glenwood

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →